For the complete report, get in touch with us at : info@netscribes.com Oncology pharmaceuticals market in India, a leading segment of the overall pharmaceuticals market is the fourth largest in volume and eighth largest in value in the global market. Since cancer is the second largest cause of death in the country, the Indian market is characterized by a huge demand for cancer drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the number of cancer cases, specially in lung cancer and breast cancer cases; changes in the cancer treatment scenario, development of alternative cancer therapies, increased cancer health insurance coverage and increasing amount of foreign direct investment (FDI) is helping the market to grow. The Indian Government, on its part is taking initiatives to work out public-private partnership projects (PPP) and reduce the essential drug prices. The market is expected to exhibit steady growth over the next few years. The report begins with the market overview section which provides an insight into the global market, highlighting the market size and growth. It then moves onto the Indian market, with a focus on market size and growth. It also provides import and export figures of cancer drugs in India in terms of value. Regional break-up of the imports and exports have been included. An analysis of the drivers explains the factors for growth of the industry including increasing cancer cases, changes in the treatment scenario, development of alternative cancer therapies, increasing FDI and increase in the number of cancer health insurances. The key challenges include increased competition, drug patent problems and drug portfolio management problems. The government initiatives section highlights the PPP R&D projects started in the country. It also analyses the various initiatives undertaken to reduce prices of cancer drugs, the various cancer control programmes implemented and the changes in the custom duty structure. A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals. The competition section provides an overview of the competitive landscape in the industry. It includes a brief profile of the major players in the market along with their financials. It also includes the latest developments in the industry.

1. Insert Cover Image using Slide Master View
Do not distort
Oncology Pharmaceuticals Market-India
August 2011

2. Executive Summary
Oncology pharmaceuticals market in India is valued at INR x bn in 20—
Market Fourth largest in volume, eighth largest in value in the world market
Market is expected to grow at a CAGR of y% from20-----
Drivers: Challenges:
Increasing number of cancer cases Increased competition
Changes in the treatment scenario Drug patents problem
Drivers and
LE
Development of alternative cancer Drug Portfolio management
Challenges therapies
P
Increase in cancer insurances
Increase in FDI
Government
Initiatives
Reforms in tax structure
Reduction in drug prices
SAM
Public –Private Partnership (PPP) programmes
Drug control programmes
Phases of clinical trial
Drug regulation
Approval and licensing of drugs
and patents Patents
Highly fragmented market with large number of players
Major foreign players in the market include Company 1,Company 2,Company 3etc
Competition
Major domestic companies include Company 4, Company 5, Company 6, among others
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT 2

3. •Market Overview
•Drivers & Challenges
•Government Initiatives
•Drug regulation and patents
•Competition
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT 3

4. Indian oncology pharma market has grown enormously over
the last few years
Indian market-overview Market size
INR bn
•Fourth largest in volume, eighth largest in
50
value in the world market g
40 Y%
LE
•Expected to reach INR y bn in 20-- f
30 e
d
•Cancer is the second largest cause of death in c
P
20 b
a
the country 10
AM
•According to the National Cancer Registry
Program (NCRP) there are z mn cancer
S
patients at any point of time
•X cancer related deaths each year
0
2010 2011e 2012e
Increase in cancer cases
2013e 2014e 2015e 2016e
•Oral and lung cancer are the most common in In ‘000
Z%
males, while in females, cervical, followed by 1,200 Y
X
breast and ovarian cancer are the most 1,000
common 800
600
•Availibilty of xx oncologists per yy people in
400
India 200
0
2010 2020e
Source:
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT 4

5. A huge volume of cancer drugs is exported to many
countries…
Exports of oncological pharmaceuticals Total Exports
•Highly fragmented market with many INR mn
domestic manufacturers lead to huge volume 3,000 E5
of exports e% E4
2,000
E
•Exports to more than k countries E3
•Country 1 and Country 2 account for the
highest exports
PL 1,000
0
E1
E2
Exports – Region wise (2008-09)
SAM 2005-06 2006-07
Exports – Region wise (2009-10)
2007-08 2008-09 2009-10
Country 1 Country 7 Country 1
i1
Country 2 Country 8 Country 2
e1
i 12 Country 3 Country 9 e7 Country 3
Country 4 Country 10 Country 4
i2 Country 5 Country 11 Country 5
Country 6 Others Country 6
i11 i10
i9 i3 e6 e2 Country 7
i8 e5
i7 i6 i4 e4 e3
i5
Source: Note: All figures are for financial year
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT 5

6. Drivers & Challenges
Drivers Challenges
Increasing number of cancer cases Increased competition
Changes in the treatment scenario Drug patent problems
Development of alternative cancer
Drug portfolio management
therapies
Increase in cancer insurances
Increase in the amount of FDI
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT 6

7. Government initiatives
Reforms in tax structure Public-Private-partnership (PPP)
projects
Government
Initiative
Cancer control programmes Reduction in drug prices
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT 7

8. Major domestic players in the market (1/9)
Company Snapshot: Company 1
Corporate Information Financial Performance
Revenue Revenue Profit
Headquarters City 1, country 1
INR tn INR bn
Profit / Loss
Founded 19-- 3 2.0
r2 r3 r4
r1 1.5
2
Products Product 1, product 2, product 3 1.0
1
LE
0.5
Key People Person X, CEO
0 0.0
Business Highlights
MP 2007 2008 2009 2010
A
• Has n employees worldwide, with offices in over m countries
S
• Operates in India through its subsidiary company 2
• Oncology products include Product 1, for treating breast cancer and Product 2
• Has recently launched two more cancer drugs in the market- Product 3 and Product 4
• Cancer drugs in pipeline include Product 5 in Phase 1 and Product 6 in phase 2 trials
• Is one of the largest collaborators in the industry with and work with academic institutions ,governments and other
pharmaceutical companies to increase R & D
Source: Company Website; Capital IQ; Note: Figures are for year ending 31st December
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT 8

9. Thank you for the attention
The Oncology Pharmaceuticals Market – India report is part of Netscribes’ Healthcare Industry
Series.
For more detailed information or customized research requirements please contact:
Tamojit Roy Gagan Uppal
Phone: +91 33 4064 6215 Phone: +91 22 4098 7530
E-Mail: tamojit.roy@netscribes.com E-Mail: gagan.uppal@netscribes.com
Research on India is a product of Netscribes (India) Pvt. Ltd. Research on India is dedicated to disseminating information and providing quick
insights on “hot” industries in India and other emerging markets. Track our new releases and major updates in these industries on
About Netscribes
Netscribes is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &
business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true
value proposition that draws upon a vast knowledge base. Netscribes is a one-stop shop designed to fulfil clients’ profitability and growth
objectives.
Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Research on India,
Netscribes (India) Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the
sole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT 9